

(43) International Publication Date
19 December 2024 (19.12.2024)(10) International Publication Number
WO 2024/257012 A1

(51) International Patent Classification:

C07D 487/08 (2006.01) A61K 31/4995 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2024/055801

(22) International Filing Date:

13 June 2024 (13.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/508,027 14 June 2023 (14.06.2023) US
63/555,123 19 February 2024 (19.02.2024) US(71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151-85,
Södertälje (SE).

(72) Inventors: **LEE, Esther Cheng Yin**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **SCOTT, James**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **GOPALSAMY, Ariamala**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **GINGIPALLI, Lakshmaiah**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **SCHNEIDER, Michael**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **REICHL, Kyle David**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **MARCYK, Paul Tomas**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **REIMANN, Christopher Elias**; c/o AstraZeneca Pharmaceu-

ticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **LICHTOR, Phillip**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **WALTON, Laura**; ASTRAZENECA INTELLECTUAL PROPERTY, Eastbrook House, Shaftesbury Road, Cambridge Cambridgeshire CB2 8BF (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(54) Title: 3-[3-AMINO-6-(2-HYDROXYPHENYL)PYRIDAZIN-4-YL]-3,8-DIAZABICYCLO[3.2.1]OCTANE DERIVATIVES AS SMARCA2 DEGRADING PROTACS FOR THE TREATMENT OF CANCER



(57) Abstract: The present disclosure provides compounds represented by Formula (A), or a pharmaceutically acceptable salt and/or stereoisomer thereof: Formula (A), wherein E is: Formula (I), Formula (II), or Formula (III); wherein R^a, R^b, R^c, R⁷, R⁸, R⁹, R¹⁰, X³, W, L, and E are as defined in the specification. Compounds represented by Formula (A) are SMARCA2 protein degraders and are thus useful for treating cancer and other diseases.

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*